Moleculin Biotech, Inc. 8-K

What Happened
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on January 20, 2026 to disclose, under Regulation FD, that it has posted a corporate investor presentation dated January 2026 on the company’s website. The presentation is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: January 20, 2026 (Form 8-K).
• Item reported: 7.01 (Regulation FD Disclosure) — corporate presentation posted publicly.
• Exhibit included: 99.1 — Investor Presentation dated January 2026.
• Filing also includes an Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8-K signals the company has made updated investor materials available to the public, ensuring broad, simultaneous disclosure under Regulation FD. Retail investors should review the January 2026 presentation (Exhibit 99.1 or on the company website) for the latest corporate overview, strategic updates, or any data the company chose to present.